Related Experiment Video
Updated: Jul 2, 2026
06:51
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Kidney Transplantation Post-Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma
Zahraa Khan1, Darshana M Dadhania1, Eugene Brailovski2
1Department of Medicine, Division of Nephrology, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
Summary
Kidney transplantation is now feasible after chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma (MM). This case study shows successful kidney transplant in an MM patient achieving minimal residual disease (MRD)-negative status post-CAR T-cell therapy.
Area of Science:
- Hematology
- Nephrology
- Immunology
Background:
- Kidney disease impacts many multiple myeloma (MM) patients, often leading to poor prognosis.
- Kidney transplantation is seldom performed in MM due to relapse and rejection risks.
- Advances in chimeric antigen receptor (CAR) T-cell therapy offer new possibilities for MM patients.
